For many years now, there have been subsets of specialists and patients who have argued that the “standard” serum testosterone level of 50 ng/dl, used by regulatory authorities and others as a measure indicating a castrate level of serum testosterone, is too high. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castrate, dhydrotestosterone, estosterone, level, serum | 18 Comments »
Discussions about the pros and cons of testosterone replacement therapy (TRT) in relation to (a) stimulating risk for prostate cancer in men who have not been diagnosed and (b) recurrence of prostate cancer among men who have been diagnosed and treated often aren’t entirely clear about a very key factor. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: hypogonadism, replacement, risk, serum, testosterone, TRT | 18 Comments »
For the past 40 years, the formal level of “effectiveness” of androgen deprivation therapy (ADT, also known as “hormone” therapy) for men treated for high-risk, progressive, and/or metastatic prostate cancer has been a serum testosterone level of < 50 ng/dl (equivalent to < 1.7 nmol/l). However, … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, serum, testosterone | 7 Comments »
A new report from a group of Italian researchers has suggested that circulating serum testosterone (T) levels in the blood may be a risk for upgrading and upstaging among men initially diagnosed with low-risk prostate cancer who are managed on active surveillance. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active, risk, serum, surveillance, testosterone | 1 Comment »
Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, hormone, serum, testosterone | 48 Comments »
We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, continuous, deprivation, outcome, serum, T, testosterone | 1 Comment »
For many years, the formal threshold level of serum testosterone (T) used to define medical “castration” has been < 50 ng/dl. However, it is widely recognized that this level is probably not low enough to accurately define a medically castrate state. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: medical castration, serum, testosterone, threshold | 3 Comments »
